Two biosimilars get U.S. panel’s nod | Chemical & Engineering News
Volume 94 Issue 29 | p. 15 | Concentrates
Issue Date: July 18, 2016

Two biosimilars get U.S. panel’s nod

Department: Business
Keywords: biosimilars, FDA, arthritis

An FDA advisory panel voted unanimously last week to recommend that the agency approve biosimilar versions of two multi-billion-dollar-selling arthritis drugs. FDA often accepts such panels’ recommendations. The panel voted 20-0 in support of Sandoz’s version of Enbrel, an Amgen drug that is used to treat arthritis and psoriasis. The panel also voted 26-0 in favor of approving Amgen’s version of the AbbVie arthritis drug Humira. In the latter case, AbbVie claims to have patents that protect Humira from competition until at least 2022.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment